Skip to main content

Day: November 24, 2025

ONWARD Medical Drives Strong US ARC-EX Adoption and Achieves Important Scientific and Regulatory Milestones in Q3 2025

EINDHOVEN, the Netherlands, Nov. 24, 2025 (GLOBE NEWSWIRE) — ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injuries (SCI) and other movement disabilities, today announced its results for the third quarter of 2025 and provides a comprehensive business update:Commercial traction: The Company met its objective of 40 ARC-EX® Systems sold in Q3. Regulatory milestones: The US Food and Drug Administration (FDA) approved an investigational device exemption (IDE) for the ARC-IM® System, allowing the initiation of the Empower BP global pivotal study. The Company received CE Mark certification for the ARC-EX System. In November, the FDA also cleared the ARC-EX System for home use in the US. Science...

Continue reading

BNP PARIBAS LAUNCHES A SHARE BUYBACK PROGRAMME OF EUR 1.15 BILLION FOR THE 2025 FINANCIAL YEAR RESULTS

PRESS RELEASE Paris, 24 November 2025 Following the approval of the European Central Bank, BNP Paribas announces today the launch of its share buyback programme related to the 2025 financial year results for a maximum amount of EUR 1.15 billion. A contract was concluded with an investment services provider acting independently, entrusted with an irrevocable instruction to purchase the shares. The purchase will start on November 24th, 2025. The shares purchased under the programme will be cancelled. BNP Paribas will provide weekly updates on the progress of the programme via a press release on BNP Paribas’ website, and via full and effective dissemination in accordance with the applicable legal provisions: https://invest.bnpparibas/en/search/reports/documents/regulated-information. The share buyback programme will be carried out in accordance...

Continue reading

Fagron strengthens EMEA leadership with acquisitions in Poland and Hungary and announces key developments for its North American business

Regulated information – inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 24 November 2025 – 7:00 AM CET Fagron strengthens EMEA leadership with acquisitions in Poland and Hungary and announces key developments for its North American business Fagron, the global leader in pharmaceutical compounding, has reinforced its EMEA position with the acquisitions of a book of business from Amara (Poland) and Magilab (Hungary). These deals support Fagron’s strategy to diversify its presence in dynamic markets and highlight its disciplined M&A approach as a driver of sustainable growth. With these transactions, Fagron has executed 10 acquisitions this year, underscoring its disciplined serial acquirer track record. The businesses combined are expected to contribute mid-teens (€m) in annual revenue, at an EBITDA margin above...

Continue reading

LexinFintech Holdings Ltd. Reports Third Quarter 2025 Unaudited Financial Results

SHENZHEN, China, Nov. 24, 2025 (GLOBE NEWSWIRE) — LexinFintech Holdings Ltd. (“Lexin” or the “Company”) (NASDAQ: LX), a leading technology-empowered personal financial service enabler in China, today announced its unaudited financial results for the quarter ended September 30, 2025. Mr. Jay Wenjie Xiao, Chairman and Chief Executive Officer of Lexin, commented, “In the third quarter, we efficiently completed our business adjustments and have smoothly transitioned our operations to comply with the new regulatory requirements. Effective October 1st, 2025, all new loans originated have been priced at or below an annual interest rate of 24%. The industry has been facing short-term compliance challenges and heightened credit risk volatility related to regulatory changes since last quarter. Despite this complex environment, Lexin has...

Continue reading

Nanox Announces $15 Million Registered Direct Offering of Common Stock

PETACH TIKVA, Israel, Nov. 23, 2025 (GLOBE NEWSWIRE) — NANO-X IMAGING LTD (“Nanox” or the “Company”, Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 3,826,530 ordinary shares (“Common Stock”) in a registered direct offering. The offering is expected to result in gross proceeds of approximately $15 million, before deducting offering expenses. The closing of the offering is expected to occur on or about November 25, 2025, subject to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes. “This successful capital raise further strengthens our balance sheet and accelerates...

Continue reading

Faraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update: FF Completes its “Dual Flywheel, Dual Bridge, and Dual Listed-Company” Structure; First batch of FX Super One Complete Sets of Components to Arrive at Port of Long Beach Next Week

The FX Super One and FF 91 2.0 will participate in the LA Auto Show, where our ride-along experiences begin. The Company welcomes everyone to give them a try and place preorders.LOS ANGELES, Nov. 23, 2025 (GLOBE NEWSWIRE) — Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF” or the “Company”), a California-based global shared intelligent electric mobility ecosystem company, today shared a weekly business update from YT Jia, Founder and Global Co-CEO of FF.  “Hi everyone, I’m coming to you from New York with Issue 30 of our CEO Weekly. I was both excited and reflective to be back at the Nasdaq MarketSite in New York after four years—this time for the official name and ticker change of our majority-owned U.S.-listed company, AIxCrypto, ticker name AIXC, and the launch of its new strategy. This moment...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.